Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| OSPRI | 2025 | Series Unknown | $30.0M | Mckinney |
| Amalgam Rx | 2025 | Series Unknown | $7.9M | Wilmington |
| Superluminal Medicines | 2025 | Corporate Round | Undisclosed | Boston |
| ArriVent | 2025 | Post Ipo Equity | $75.0M | Pennsylvania Furnace |
| Visby Medical | 2025 | Series Unknown | $55.0M | San Jose |
| Syndeio Biosciences | 2025 | Series Unknown | $90.0M | Indianapolis |
| GlycoEra | 2025 | Series B | $130.0M | Schlieren |
| Xilis | 2025 | Series Unknown | $19.4M | Durham |
| Perceive Pharma | 2025 | Series A | $15.0M | San Francisco |
| DNA Script | 2025 | Grant | $4.7M | Le Kremlin-bicêtre |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 76 | OSPRI | Series Unknown | $30.0M | Mckinney, United States |
| 77 | Amalgam Rx | Series Unknown | $7.9M | Wilmington, United States |
| 78 | Superluminal Medicines | Corporate Round | Undisclosed | Boston, United States |
| 79 | ArriVent | Post Ipo Equity | $75.0M | Pennsylvania Furnace, United States |
| 80 | Visby Medical | Series Unknown | $55.0M | San Jose, United States |
| 81 | Syndeio Biosciences | Series Unknown | $90.0M | Indianapolis, United States |
| 82 | GlycoEra | Series B | $130.0M | Schlieren, Switzerland |
| 83 | Xilis | Series Unknown | $19.4M | Durham, United States |
| 84 | Perceive Pharma | Series A | $15.0M | San Francisco, United States |
| 85 | DNA Script | Grant | $4.7M | Le Kremlin-bicêtre, France |
OSPRI is updating the infectious illness testing plan.
Amalgam Rx develops and distributes digital health products that support patients and healthcare providers in decision-making.
Superluminal Medicines is a generative biological and chemical company that innovates drug discovery and development processes.
ArriVent develops pharmaceutical products to cure presently untreatable cancer.
Visby Medical is a diagnostics company that develops polymerase chain reaction diagnostic tests for the detection of infectious diseases.
Syndeio Biosciences is a newly launched biotech company pioneering precision neurotherapeutics.
GlycoEra is a biotechnology research company that produces extracellular protein degraders for the treatment of autoimmune diseases.
Xilis is an oncology and precision health company that provides technologies to diagnoses cancer.
Perceive Pharma operates as a pharmaceutical company.
DNA Script is a disruptive DNA synthesis company harnessing biology to accelerate breakthroughs in life science and human health.
PinkDx is a biotechnology company.
Medical Informatics offers solutions that give care teams access to the data they need to take action for alarm management and safety.
ALENTIS Therapeutics is a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer.
Orasis Pharmaceuticals is an ophthalmic pharmaceutical company that develops eye drops for the treatment of presbyopia.
Noetik is an AI-native biotechnology company that applies machine learning to large-scale human multimodal spatial omics datasets.
EGenesis is a gene editing and genome engineering company developing human-compatible engineered organs to treat diseases.
Elektrofi develops hyper concentration microparticle technology for subcutaneous biologic medicine delivery.
Recursion Pharmaceuticals is a biotech company that develops a drug discovery platform and pipeline with machine learning.
Neumora Therapeutics operates as a clinical-stage biotechnology company.
Clasp Therapeutics offers to reach of immuno-oncology with novel precision medicines that enable the immune system.
NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients.
Lassen Therapeutics develops antibody biotherapeutics to help improve the lives of patients suffering from serious diseases.
Centenara Labs is an integrated biotechnology platform company that invests in people and ideas to develop therapies.
Spiral Therapeutics is a clinical-stage pharmaceutical company delivering therapies for hearing loss.
Georgiamune is a biotechnology company developing next-generation immunotherapeutics for cancer and autoimmune diseases.
Catalio Capital Management has invested in 110 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Catalio Capital Management's top investment sectors include Biotechnology, Medical, Health Care, Pharmaceutical, Life Science. The firm invests across 21 different industry categories.
Among tracked funding rounds, Recursion Pharmaceuticals received $200.0M in a Post Ipo Equity round. Catalio Capital Management's total known invested capital is $5.2B.
Catalio Capital Management's average investment size is $72.8M across its portfolio of 110 companies.
Recent Catalio Capital Management portfolio additions include OSPRI, Amalgam Rx, Superluminal Medicines, ArriVent, Visby Medical. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors